Sutro Biopharma Inc
STRO0.900USD
+0.175+24.17%
Cierre 04/23, 16:00（ET）Cotizaciones retrasadas 15 min
74.27MCap. mercado
PérdidaP/E TTM
Información de Sutro Biopharma Inc Compañía
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Información de la empresa
Código de la empresaSTRO
Nombre de la empresaSutro Biopharma Inc
Fecha de salida a bolsaSep 27, 2018
Fundada en2003
Director ejecutivoMs. Jane Chung
Número de empleados310
Tipo de títulosOrdinary Share
Fin del año fiscalSep 27
Dirección111 Oyster Point Blvd.
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Teléfono16503928412
Sitio Webhttps://www.sutrobio.com/
Código de la empresaSTRO
Fecha de salida a bolsaSep 27, 2018
Fundada en2003
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
52.08K
+35.51%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
+454.77%
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sukhi Jagpal
Ms. Sukhi Jagpal
Director
Director
--
--
Mr. Joseph M. Lobacki
Mr. Joseph M. Lobacki
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Panek
Mr. James P. (Jim) Panek
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
52.08K
+35.51%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
+454.77%
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
No datos encontrados
No datos encontrados
Por negocio
Por región
No datos encontrados
Accionista
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Suvretta Capital Management, LLC
8.91%
BlackRock Institutional Trust Company, N.A.
7.51%
RA Capital Management, LP
5.29%
The Vanguard Group, Inc.
5.02%
Kynam Capital Management LP
4.35%
Other
68.92%
Estadísticas de accionistas
Accionista
Proporción
Suvretta Capital Management, LLC
8.91%
BlackRock Institutional Trust Company, N.A.
7.51%
RA Capital Management, LP
5.29%
The Vanguard Group, Inc.
5.02%
Kynam Capital Management LP
4.35%
Other
68.92%
Tipo
Accionista
Proporción
Hedge Fund
33.76%
Investment Advisor/Hedge Fund
24.76%
Investment Advisor
14.75%
Corporation
3.25%
Research Firm
3.03%
Venture Capital
2.86%
Individual Investor
1.15%
Pension Fund
0.46%
Bank and Trust
0.12%
Other
15.86%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo de informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
282
70.21M
83.81%
-8.43M
2024Q4
299
65.68M
79.84%
-13.78M
2024Q3
295
64.44M
78.61%
-17.80M
2024Q2
286
64.98M
79.66%
-15.82M
2024Q1
291
55.64M
88.75%
-15.66M
2023Q4
302
58.38M
95.62%
-12.57M
2023Q3
306
61.36M
101.61%
-9.98M
2023Q2
312
60.26M
100.55%
-11.07M
2023Q1
320
58.55M
98.20%
-11.55M
2022Q4
332
54.70M
96.18%
-13.75M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Suvretta Capital Management, LLC
7.46M
8.91%
+275.00K
+3.83%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.29M
7.51%
+542.02K
+9.43%
Dec 31, 2024
RA Capital Management, LP
4.43M
5.29%
+4.43M
--
Mar 28, 2025
The Vanguard Group, Inc.
4.21M
5.02%
+13.43K
+0.32%
Dec 31, 2024
Kynam Capital Management LP
3.64M
4.35%
+1.57M
+76.22%
Dec 31, 2024
Merck & Co Inc
2.72M
3.25%
+2.72M
--
Dec 31, 2024
Vestal Point Capital, LP
2.57M
3.07%
+2.57M
--
Dec 31, 2024
Citadel Advisors LLC
2.46M
2.93%
+332.00K
+15.61%
Dec 31, 2024
Point72 Asset Management, L.P.
2.20M
2.62%
-799.91K
-26.69%
Dec 31, 2024
Samsara BioCapital, LLC
2.20M
2.62%
--
--
Dec 31, 2024
Ver más
ETF relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Range Cancer Immunotherapy ETF
0.76%
Invesco NASDAQ Future Gen 200 ETF
0.31%
ALPS Medical Breakthroughs ETF
0.11%
Avantis US Small Cap Equity ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Ver más
Range Cancer Immunotherapy ETF
Proporción0.76%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.31%
ALPS Medical Breakthroughs ETF
Proporción0.11%
Avantis US Small Cap Equity ETF
Proporción0.01%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
iShares Micro-Cap ETF
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
Fidelity Enhanced Small Cap ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
No datos encontrados
División de acciones
Fecha
Tipo
Relación
No datos encontrados
Fecha
Tipo
Relación
No datos encontrados